PARIS, France, January 2, 2024 at 6 p.m. (CET) – Pharnext SCA (FR001400JXB0 – ALPHA)
(the “Company”), a biopharmaceutical company at an advanced clinical stage developing new therapies for neurodegenerative diseases without satisfactory therapeutic solutions, presents the number of shares and voting rights making up the share capital, in accordance with the provisions of article L.233-8 II of the Commercial Code and article 223-16 of the General Regulations of the Financial Markets Authority.
|
Date |
Number of shares making up the capital |
Number of GROSS voting rights |
Number of NET voting rights |
12/31/2023 | 1,789,680,376 | 1,789,680,376 | 1,789,680,376 |
Furthermore, the company recalls that, since 1
er
January 2023, the number of shares issued each month by the company breaks down as follows:
|
Wording |
OCEANE CONVERSION |
BSA EXERCISE | ||
Number of OCEANEs converted | Number of actions created | Number of BSAs | Number of actions created | |
|
Before regrouping | ||||
January 2023 | 200 | 240 010 495 | 20,302,608 | 20,302,608 |
February 2023 | 68 | 578 132 700 | 20,177,456 | 20,177,456 |
March 2023 | 150 | 5,447,619,045 | 442,838,613 | 442,838,613 |
April 2023 | 0 | 0 | 33,774,890 | 33,774,890 |
|
After grouping | ||||
May 2023 | 107 | 1,712,176 | 554 621 | 554 621 |
June 2023 | 200 | 38,474,975 | 8,434,524 | 8,434,524 |
July 2023 | 100 | 430 508 248 | 64,537,465 | 64,537,465 |
August 2023 | 48 | 3,221,422,857 | 143,009,795 | 143,009,795 |
|
After grouping | ||||
September 2023 | 232 | 6,027,065 | 365,038 | 365,038 |
October 2023 | 130 | 27,787,467 | 5,973,992 | 5,973,992 |
November 2023 | 135 | 183 158 388 | 120,663,807 | 120,663,807 |
December 2023 | 99 | 945 381 396 | 499 541 356 | 499 541 356 |
The number of newly issued shares in respect of conversions as well as the total number of shares in circulation are kept on the Company’s website: HERE
Warning :
The company Pharnext has set up (i) financing in the form of OCEANE-BSA with the company Global Tech Opportunities 13, which, after having received the shares resulting from the conversion or exercise of these instruments, has not not intended to remain a shareholder of the company, and (ii) financing in OS which were then transferred to a trust, which is now responsible for their equitization.
The shares resulting from the conversion or exercise of the above-mentioned securities are generally sold in the market at very short notice, which can create strong downward pressure on the share price. In the specific case of the trust, the shares are sold on the market according to the terms set out in the trust agreement.
Shareholders may suffer a loss of their invested capital due to a significant decrease in the value of the company’s stock, as well as significant dilution due to the number of securities issued to the company Global Tech Opportunities 13 and/or trust.
Investors are advised to be very vigilant before making the decision to invest (or remain invested) in the securities of the company admitted to trading which carries out such dilutive financing transactions, particularly when they are carried out successively. The company recalls that this dilutive financing operation is not the first that it has implemented.
About Pharnext
Pharnext is a late-stage clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases currently without satisfactory therapeutic solutions. Pharnext has a new drug candidate, PXT3003, in development for Charcot-Marie-Tooth disease type 1A (CMT1A), a rare and debilitating hereditary peripheral neuropathy. PXT3003 benefits from orphan drug status in Europe and the United States. More information on www.pharnext.com.
Pharnext is listed on the Euronext Growth market in Paris (ISIN code: FR001400JXB0).
Contacts
|
Financial Press Relations NEWS finance & communication Anne-Charlotte Dudicourt [email protected] +33 (0)1 53 67 36 32 |
Investor Relations NEWS finance & communication Jérôme Fabreguettes Leib [email protected] +33 (0)1 53 67 36 78 |
[1]
Consolidation by exchange of 10,000 old shares for 1 new share
[2]
Consolidation by exchange of 5,000 old shares for 1 new share
This publication has the “🔒 Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
lpieaJWclpfHyGycY55naJNmb5qSm2aZlmOXm2KbmJ+Xb29ox2eTZsfLZnFkmW5n
– To control this key:
https://www.security-master-key.com.
Regulated information:
Total number of voting rights and capital:
– Information relating to the total number of voting rights and shares making up the capital
Full and original press release in PDF format:
https://www.actusnews.com/news/83491-2024.01.02_pharnext_ddv.pdf
© Copyright Actusnews Wire
Receive future company press releases free of charge by email by subscribing to www.actusnews.com